Literature DB >> 12115996

Hepatitis C virus-Epstein-Barr virus interaction in patients with AIDS.

Dominique Challine1, Marlyse Buisson, Michel Cadilhac, Georgios Germanidis, Irene Joab, Muriel Eliaszewicz, Eric Caumes, Antoine Flahault, Anne-Marie Fillet, Jean-Michel Pawlotsky, Jean-Marie Seigneurin.   

Abstract

Immortalization of B cells by Epstein-Barr virus (EBV) and their subsequent proliferation leads to B-cell non-Hodgkin's lymphoma in immunocompromised patients. The role of hepatitis C virus (HCV) in B-cell non-Hodgkin's lymphoma has recently been raised, and an interaction between HCV and EBV is supported by recent in vitro experiments. The aim of this study was to investigate in vivo interactions between HCV and EBV in patients with AIDS, i.e., patients exposed to the risk of EBV-related B-cell non-Hodgkin's lymphoma. A total of 135 patients were prospectively studied. Serological and molecular markers of HCV, EBV, and human immunodeficiency virus (HIV) infection were sought. All the patients harbored latent EBV infection, and 20% had detectable HCV RNA in serum. No significant relationship was found between HIV, HCV, and EBV viral load in peripheral blood mononuclear cells or plasma. There was no difference between anti-HCV-positive and -negative patients or between HCV RNA-positive and -negative patients with regard to the prevalence of EBV markers, especially EBV replication markers. The presence of EBV replication markers was not related to HCV RNA seropositivity or to HCV viral load. Five patients subsequently developed B-cell non-Hodgkin's lymphoma, none of whom had markers of EBV or HCV replication. These results argue against an in vivo interaction between HCV and EBV in patients with AIDS, and against a role of HCV infection in the occurrence of B-cell non-Hodgkin's lymphoma in these patients. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115996     DOI: 10.1002/jmv.10130

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  2 in total

1.  Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients.

Authors:  Lindsay M Morton; Ola Landgren; Nilanjan Chatterjee; David Castenson; Ruth Parsons; Robert N Hoover; Eric A Engels
Journal:  Blood       Date:  2007-09-12       Impact factor: 22.113

2.  Pre-stimulation of CD81 expression by resting B cells increases proliferation following EBV infection, but the overexpression of CD81 induces the apoptosis of EBV-transformed B cells.

Authors:  Ga Bin Park; Daejin Kim; Sung Jae Park; Hyun-Kyung Lee; Ji Hyun Kim; Yeong Seok Kim; Sae-Gwang Park; In-Hak Choi; Sung Ho Yoon; Youn Jae Lee; Sunghwa Paeng; Dae Young Hur
Journal:  Int J Mol Med       Date:  2015-10-13       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.